Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas:: Toward a genetic model of meningioma progression

被引:325
作者
Weber, RG
Boström, J
Wolter, M
Baudis, M
Collins, VP
Reifenberger, G
Lichter, P
机构
[1] Deutsch Krebsforschungszentrum, Abt Org Komplexer Genome 0845, D-69120 Heidelberg, Germany
[2] Univ Dusseldorf, Inst Neuropathol, D-40225 Dusseldorf, Germany
[3] Univ Dusseldorf, Zentrum Biol & Med Forsch, D-40225 Dusseldorf, Germany
[4] Karolinska Hosp, Stockholm Branch, Ludwig Inst Canc Res, S-17176 Stockholm, Sweden
[5] Karolinska Hosp, Stockholm Branch, Inst Oncol & Pathol, Div Tumor Pathol, S-17176 Stockholm, Sweden
关键词
D O I
10.1073/pnas.94.26.14719
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Nineteen benign [World Health Organization (WHO) grade I; MI], 21 atypical (WHO grade II; MH), and 19 anaplastic (WHO grade III; MIII) sporadic meningiomas were screened for chromosomal imbalances by comparative genomic hybridization (CGH), These data were supplemented by moleo ular genetic analyses of selected chromosomal regions and genes, With increasing malignancy grade, a marked accumulation of genomic aberrations was observed; i.e., the numbers (mean +/- SEM) of total alterations detected per tumor were 2.9 +/- 0.7 for MI, 9.2 +/- 1.2 for MII and 13.3 +/- 1.9 for MIII. The most frequent alteration detected in MI was loss on 22q (58%), In MII, aberrations most commonly identified were losses on 1p (76%), 22q (71%), 14q (43%), 18q (43%), 10 (38%), and 6q (33%), as well as gains on 20q (48%), 12q (43%), 15q (43%), 1q (33%), 9q (33%), and 17q (33%). In MIII, most of these alterations were found at similar frequencies, However, an increase in losses on 6q (53%), 10 (68%), and 14q (63%) was observed, In addition, 32% of MIII demonstrated loss on 9p, Homozygous deletions in the CDKV2A gene at 9p21 were found in 4 of 16 MIII (25%), Highly amplified DNA sequences were mapped to 12q13-q15 by CGH in 1 MII. Southern blot analysis of this tumor revealed amplification of CDK4 and MDM2. By CGH, DNA sequences from 17q were found to be amplified in 1 MII and 8 Mm; involving 17q23 in all cases, Despite the high frequency of chromosomal aberrations in the MII and Mm investigated, none of these tumors showed mutations in exons 5-8 of the TP53 gene, On the basis of the most common aberrations identified in the various malignancy grades, a model for the genomic alterations associated with meningioma progression is proposed.
引用
收藏
页码:14719 / 14724
页数:6
相关论文
共 64 条
[41]   Expression patterns of the p53 tumor suppressor gene and the mdm2 protooncogene in human meningiomas [J].
Pykett, MJ ;
Landers, J ;
George, DL .
JOURNAL OF NEURO-ONCOLOGY, 1997, 32 (01) :39-44
[42]  
RASHEED BKA, 1995, ONCOGENE, V10, P2243
[43]  
REIFENBERGER G, 1994, CANCER RES, V54, P4299
[44]   Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression [J].
Reifenberger, J ;
Ring, GU ;
Gies, U ;
Cobbers, JMJL ;
Oberstrass, J ;
An, HX ;
Niederacher, D ;
Wechsler, W ;
Reifenberger, G .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (07) :822-831
[45]  
REMPEL SA, 1993, CANCER RES, V53, P2386
[46]   CHROMOSOMAL INVOLVEMENT SECONDARY TO - 22 IN HUMAN MENINGIOMAS [J].
REY, JA ;
BELLO, MJ ;
DECAMPOS, JM ;
KUSAK, E ;
MORENO, S .
CANCER GENETICS AND CYTOGENETICS, 1988, 33 (02) :275-290
[47]  
RIED T, 1995, CANCER RES, V55, P5415
[48]   Mad-related genes in the human [J].
Riggins, GJ ;
Thiagalingam, S ;
Rozenblum, E ;
Weinstein, CL ;
Kern, SE ;
Hamilton, SR ;
Willson, JKV ;
Markowitz, SD ;
Kinzler, KW ;
Vogelstein, B .
NATURE GENETICS, 1996, 13 (03) :347-349
[49]   EVIDENCE FOR THE COMPLETE INACTIVATION OF THE NF2 GENE IN THE MAJORITY OF SPORADIC MENINGIOMAS [J].
RUTTLEDGE, MH ;
SARRAZIN, J ;
RANGARATNAM, S ;
PHELAN, CM ;
TWIST, E ;
MEREL, P ;
DELATTRE, O ;
THOMAS, G ;
NORDENSKJOLD, M ;
COLLINS, VP ;
DUMANSKI, JP ;
ROULEAU, GA .
NATURE GENETICS, 1994, 6 (02) :180-184
[50]  
Sato K, 1996, INT J CANCER, V66, P305, DOI 10.1002/(SICI)1097-0215(19960503)66:3<305::AID-IJC6>3.0.CO